(HealthDay)—Cimzia (certolizumab pegol) injection has been approved to treat adults with nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the U.S. Food and Drug ...
The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...
May 15 -- THURSDAY, May 14 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) to treat moderate-to-severe rheumatoid arthritis, Belgian drug maker UCB ...
UCB (UCB.BR) The European marketing authorisation application for Cimzia® has been filed. Subject to approval, Cimzia® will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor ...
ATLANTA, Oct. 18, 2013 -- regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adults with active ...
* EMA has recommended the Cimzia dose dispenser cartridge for use with the re-usable ava electronic injection device in all approved indications Source text: bit.ly/2qcXlVg Further company coverage: ...
A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA. UCB developed the AutoClicks ...
WASHINGTON The Food and Drug Administration today approved Cimzia, a new drug by UCB to treat Crohn’s disease. Crohn’s disease is a chronic, inflammatory bowel disease. It has no cure and its cause is ...
The FDA has approved Cimzia (certolizumab pegol; UCB) injection for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results